This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Matteo Villain, Ph.D.
Vice President, CMC Development at Bachem Americas

Profile

Matteo joined Bachem in 2004 as Director of Research. During his career at Bachem Americas he covered both the position of VP of R&D responsible for process development, and VP of Manufacturing responsible for commercial production. In his current position as VP of CMC Development, he supports Bachem customers in identifying the activities assuring a successful CMC development. Matteo holds a Doctorate in Chemistry and Pharmaceutical Technology from University of Milano, School of Pharmacy.

Agenda Sessions

  • Mutagenic and Genotoxic Substance Control in Peptides: ICH M7 as a Guidance in the Evaluation of Peptidic APIs

    3:45pm